Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis
Metrics: PDF 636 views | HTML 456 views | ?
Emilie Dalloneau1,2, Nadine Baroukh3, Konstantinos Mavridis4, Agnès Maillet1,2, Fabien Gueugnon1,2, Yves Courty1,2, Agnès Petit1,2, Thomas Kryza5, Maguy Del Rio6, Serge Guyetant1,2, Diana Carolina Cadena Castaneda3, Christine Dhommée3, Christophe Arnoult3, Andreas Scorilas4, Valérie Gouilleux-Gruart3,7,*, Nathalie Heuzé-Vourc’h1,2,*
1Université François Rabelais, UMR 1100, Tours, France
2INSERM, Centre d’Etude des Pathologies Respiratoires, UMR 1100, Tours, France
3Université François Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France
4Department of Biochemistry and Molecular Biology, University of Athens, Panepistimiopolis, Athens, Greece
5Institute of Health and Biomedical Innovation, Translational Research Institute, Queensland University of Technology, Brisbane, Queensland, Australia
6Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France
7CHRU de TOURS, Laboratoire d’Immunologie, Tours, France
*These authors have contributed equally to this work
Nathalie Heuzé-Vourc’h, email: firstname.lastname@example.org
Keywords: FcRn, non-small cell lung cancer, prognosis, marker, antitumor immunity
Received: October 28, 2015 Accepted: May 14, 2016 Published: June 15, 2016
Lung cancer is the leading cause of cancer-related death worldwide. Although the recommended tumor, node and metastasis (TNM) classification and stage determination are important to select therapeutic options for patients with non-small cell lung carcinoma (NSCLC), additional molecular markers are required to indicate the prognosis, in particular within a specific stage, and help with the management of patients.
Because neonatal Fc receptor (FcRn) has recently been involved in colon cancer immunosurveillance, we measured its expression in non-cancerous and NSCLC lung tissues and evaluated its prognostic value in overall survival for patient with NSCLC. FcRn expression was determined at both mRNA and protein levels on cancerous and adjacent non-cancerous tissues from 80 NSCLC patients. In NSCLC, FcRn was mainly found in resident and tumor infiltrating immune cells. The corresponding mRNA and protein were significantly less abundant in lung tumor than non-cancerous tissue. Moreover, analysis of our cohort and datasets from the public data bases show that FCGRT mRNA down-regulation is a robust and independent, unfavorable predictive factor of NSCLC patient survival. We conclude that FCGRT mRNA expression may be a useful additional marker for immunoscoring, reflecting tumor immune system, and help in the decision-making process for NSCLC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.